Policy

Vialdyne is for licensed B2B buyers only.

Vialdyne supplies peptide active pharmaceutical ingredients (APIs) for compounding-pharmacy formulation under applicable regulations. Our catalogue, pricing, and inquiry workflows are designed for, and restricted to, the following licensed entities:

• U.S. 503A compounding pharmacies licensed by their state Board of Pharmacy and operating under USP <797> / <800>
• U.S. 503B outsourcing facilities registered with the FDA under section 503B of the FD&C Act
• EU prescription compounders licensed under their national pharmacy authority and aligned with EU GMP Annex 1
• Licensed pharmaceutical wholesalers and distributors with current regional registration (e.g. VAWD/NABP in the U.S., MIA in the EU)

Who we do not serve

Vialdyne does not sell to private individuals, online resellers without licence, gyms or clinics not operating under a compounding-pharmacy framework, or any buyer who cannot present a valid pharmacy or wholesale licence on request. Vialdyne's products are not finished drugs and are not intended for direct administration to any person.

How licence verification works

1. Every inquiry must include a pharmacy or wholesaler licence number on submission.
2. Before the first quotation, our team verifies the licence against the issuing authority's public registry, or requests a copy of the licence directly.
3. Once verified, the buyer's licence remains on file for subsequent orders. Renewals are confirmed annually.
4. Buyers whose licence cannot be verified, or who are flagged for unauthorised resale, are removed from the inquiry pipeline without further response.

Regulatory context

Certain peptides on Vialdyne's catalogue are currently the subject of FDA Pharmacy Compounding Advisory Committee (PCAC) review, including the 7 peptides under evaluation in July 2026 (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Buyers are responsible for verifying compounding eligibility against the current 503A bulks list in their destination market at the time of dispense. Vialdyne does not warrant that any catalogue item is appropriate for any specific clinical formulation; that determination rests with the licensed pharmacist or QA director receiving the lot.

Questions about this policy? Email compliance@vialdyne.com.